The global antisense oligonucleotide for neuromuscular disorders market size was valued at USD 2.03 billion in 2024 and is expected to reach USD 4.87 billion by 2032, at a CAGR of 11.50% during the forecast period. The global business landscape is undergoing a transformation, with industries increasingly leaning on deep research and actionable insights to make...